LivaNova (NASDAQ:LIVN) Posts Quarterly Earnings Results, Beats Estimates By $0.28 EPS

LivaNova (NASDAQ:LIVN) released its earnings results on Wednesday. The company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28, Briefing.com reports. The company had revenue of $294.90 million during the quarter, compared to analysts’ expectations of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.43 EPS. LivaNova updated its FY 2024 guidance to 3.050-3.150 EPS and its FY24 guidance to $3.05-3.15 EPS.

LivaNova Price Performance

Shares of LIVN opened at $64.15 on Friday. LivaNova has a 1 year low of $42.75 and a 1 year high of $64.36. The company has a 50 day simple moving average of $54.57 and a two-hundred day simple moving average of $50.94. The company has a quick ratio of 2.51, a current ratio of 3.17 and a debt-to-equity ratio of 0.50.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LIVN shares. Robert W. Baird upped their target price on shares of LivaNova from $58.00 to $66.00 and gave the stock a “neutral” rating in a research report on Thursday. Barclays boosted their price objective on shares of LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Mizuho lifted their price target on shares of LivaNova from $75.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $72.00 target price on shares of LivaNova in a report on Wednesday. Finally, StockNews.com raised shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $66.20.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.